1. Scrip
  2. >>Therapy Areas

OSE Open To Partners For Late-Stage Assets

 
• By Jessica Merrill

CEO Nicolas Poirier talked to Scrip about the development plans for two late-stage assets: a therapeutic cancer vaccine and an IL-7 antagonist for ulcerative colitis.

(Shutterstock)
Key Takeaways
  • OSE is developing the therapeutic cancer vaccine Tedopi in Phase III and IL-7 antagonist lusvertikimab for ulcerative colitis in Phase II.
  •  CEO Nicolas Poirier spoke in an interview about the company’s development strategy and partnering plans.
  • OSE’s new Phase III trial for Tedopi in NSCLC was informed by learnings from a prior Phase III study that was stopped early due to COVID-19.

OSE Immunotherapeutics is developing two late-stage assets in different therapeutic areas, cancer and ulcerative colitis, and has a pipeline of products in earlier development, both independently and with partners

“We are happy to have two options, two late-stage programs,” Poirier said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.